Literature DB >> 22975349

Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D.

Zhaoxia Huo1, Jiang-Chuan Ye, Jinjin Chen, Xiaoping Lin, Zhao-Nian Zhou, Xin-Ran Xu, Chang-Ming Li, Man Qi, Dandan Liang, Yi Liu, Jun Li.   

Abstract

Cyclic adenosine 3',5'-monophosphate (cAMP), which is synthesized by adenylyl cyclase (AC) and degraded by phosphodiesterase (PDE), plays crucial roles in the regulation of multiple cellular functions and physiological processes. Prolyl hydroxylase domain (PHD) proteins, which belong to a family of dioxygenases that function as oxygen sensors through their hydroxylation activity, have been implicated in multiple signaling pathways. Here, we aimed to determine whether PHD played a role in regulating intracellular cAMP level in cardiomyocytes. Through the overexpression/knockdown of the PHD gene and the measurement of the cAMP content, we found that PHD2, but not PHD1 or PHD3, acts as a regulator of intracellular cAMP. In neonatal rat cardiomyocytes and H9c2 cells, the overexpression of PHD2 increased the intracellular cAMP level, whereas the PHD2 knockdown reduced it. There was no alteration in the AC expression or activity in cells that overexpressed or downregulated PHD2. The overexpression of PHD2 decreased both the protein expression and the activity of phosphodiesterase 4D (PDE4D), whereas the PHD2 knockdown increased the PDE4D expression and activity. Co-immunoprecipitation experiments revealed a direct binding between PHD2 and PDE4D and liquid chromatography-tandem mass spectrometry analyses identified the specific hydroxylation sites on PDE4D. In conclusion, PHD2 may directly interact with PDE4D to function as a novel regulator of the intracellular cAMP levels in cardiomyocytes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22975349     DOI: 10.1016/j.bbrc.2012.09.005

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

2.  Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates.

Authors:  Matthew E Cockman; Kerstin Lippl; Ya-Min Tian; Johanna Myllyharju; Christopher J Schofield; Peter J Ratcliffe; Hamish B Pegg; William D Figg; Martine I Abboud; Raphael Heilig; Roman Fischer
Journal:  Elife       Date:  2019-09-10       Impact factor: 8.140

Review 3.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

Review 4.  The role of PHD2 mutations in the pathogenesis of erythrocytosis.

Authors:  Betty Gardie; Melanie J Percy; David Hoogewijs; Rasheduzzaman Chowdhury; Celeste Bento; Patrick R Arsenault; Stéphane Richard; Helena Almeida; Joanne Ewing; Frédéric Lambert; Mary Frances McMullin; Christopher J Schofield; Frank S Lee
Journal:  Hypoxia (Auckl)       Date:  2014-07-01

Review 5.  PHD2: from hypoxia regulation to disease progression.

Authors:  Ana M Meneses; Ben Wielockx
Journal:  Hypoxia (Auckl)       Date:  2016-04-11

6.  The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells.

Authors:  Yousra Ajouaou; Abdulkader Azouz; Anaëlle Taquin; Sebastien Denanglaire; Hind Hussein; Mohammad Krayem; Fabienne Andris; Muriel Moser; Stanislas Goriely; Oberdan Leo
Journal:  Elife       Date:  2022-02-22       Impact factor: 8.713

Review 7.  Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.

Authors:  Mengqiu Miao; Mengqiu Wu; Yuting Li; Lingge Zhang; Qianqian Jin; Jiaojiao Fan; Xinyue Xu; Ran Gu; Haiping Hao; Aihua Zhang; Zhanjun Jia
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.